From the Professor..., page-168

You CANNOT infer anything from the data you showed. For example, the tumor growth for IV cholangiocarcinoma was due to pseudoprogression but you can’t say whether the other cases were or not. And tumor growth is not necessarily evidence that CF33 isn’t working. It’s possible that at these lower doses the rates of growth were reduced. There is no control population to compare with so we just don’t know. So how can you claim the virus had no effect, much less claim that any growth is proof of virus failure? In any case, Phase 1 is supposed to test for safety, not efficacy. Your belittling the bile duct successes so far is ridiculous. It’s a cancer much more prevalent in Asia than in the West so the market is larger than just the USA. You don’t think it’s promising that CF33 might demonstrate proof of concept in at least one indication? But at least you seem happy to wait for more data.